Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 316.27M | 277.25M | 232.28M | 722.68M | 439.44M | 46.55M |
Gross Profit | 261.97M | 227.80M | 182.12M | 460.53M | 265.87M | 32.64M |
EBITDA | -34.56M | 45.70M | 9.67M | 307.70M | 95.71M | -46.84M |
Net Income | -52.73M | 27.31M | -6.39M | 293.16M | 76.71M | -75.24M |
Balance Sheet | ||||||
Total Assets | 918.45M | 986.26M | 997.10M | 985.85M | 1.04B | 353.27M |
Cash, Cash Equivalents and Short-Term Investments | 613.73M | 713.83M | 742.30M | 624.39M | 545.95M | 165.04M |
Total Debt | 285.50M | 254.42M | 256.91M | 258.01M | 257.38M | 217.85M |
Total Liabilities | 424.29M | 389.46M | 375.02M | 404.84M | 816.87M | 294.58M |
Stockholders Equity | 494.16M | 596.80M | 622.07M | 581.01M | 222.37M | 58.69M |
Cash Flow | ||||||
Free Cash Flow | 66.07M | 60.16M | 96.46M | 55.58M | 326.05M | -103.32M |
Operating Cash Flow | 76.27M | 66.51M | 100.56M | 62.72M | 335.53M | -92.25M |
Investing Cash Flow | 109.60M | -18.04M | -153.93M | -316.00M | 14.22M | -26.53M |
Financing Cash Flow | -200.20M | -102.02M | 1.39M | 19.52M | 55.78M | 109.50M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
76 Outperform | $2.55B | 39.70 | 6.38% | ― | 5.55% | 1145.24% | |
68 Neutral | $1.36B | 10.93 | 18.32% | ― | 1.37% | -18.10% | |
66 Neutral | $2.08B | ― | -2.82% | ― | 38.68% | -160.14% | |
61 Neutral | $1.22B | ― | -15.57% | ― | 2.25% | -301.59% | |
54 Neutral | $1.17B | 64.45 | -9.28% | ― | 26.66% | -419.55% | |
51 Neutral | $7.91B | -0.36 | -41.71% | 2.23% | 23.45% | -1.86% | |
41 Neutral | $1.18B | ― | -16.34% | ― | -1.03% | 8.13% |
On August 21, 2025, Dynavax announced positive topline results from Part 1 of its Phase 1/2 clinical trial for Z-1018, a novel shingles vaccine candidate. The trial showed that Z-1018 has comparable immune responses to Shingrix, with a favorable tolerability profile, marking a significant step in Dynavax’s efforts to disrupt the shingles vaccine market. Plans are underway to advance Z-1018 into Part 2 of the trial for adults aged 70 and older, aiming to further de-risk the program before Phase 3 development.
On April 14, 2025, Dynavax held its Annual Meeting where stockholders elected four Class I directors to serve until the 2028 meeting. The meeting also saw the approval of executive compensation, the ratification of Ernst & Young LLP as the independent auditor, and the amendment of the Certificate of Incorporation to declassify the Board. However, a stockholder proposal to amend the bylaws without stockholder approval was not passed.